- Home
- ALNY vs JD Comparison
ALNY vs JD Comparison
Compare ALNY & JD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALNY
- JD
- Stock Information
- Founded
- ALNY 2002
- JD 2006
- Country
- ALNY United States
- JD China
- Employees
- ALNY N/A
- JD N/A
- Industry
- ALNY Biotechnology: Pharmaceutical Preparations
- JD Other Specialty Stores
- Sector
- ALNY Health Care
- JD Consumer Discretionary
- Exchange
- ALNY Nasdaq
- JD Nasdaq
- Market Cap
- ALNY 60.7B
- JD 48.9B
- IPO Year
- ALNY 2004
- JD 2014
- Fundamental
- Price
- ALNY $463.36
- JD $33.33
- Analyst Decision
- ALNY Strong Buy
- JD Buy
- Analyst Count
- ALNY 27
- JD 12
- Target Price
- ALNY $466.46
- JD $43.17
- AVG Volume (30 Days)
- ALNY 1.0M
- JD 14.2M
- Earning Date
- ALNY 10-30-2025
- JD 11-13-2025
- Dividend Yield
- ALNY N/A
- JD 2.91%
- EPS Growth
- ALNY N/A
- JD 29.31
- EPS
- ALNY N/A
- JD 3.57
- Revenue
- ALNY $2,461,963,000.00
- JD $176,598,313,733.00
- Revenue This Year
- ALNY $60.04
- JD $15.12
- Revenue Next Year
- ALNY $40.69
- JD $5.71
- P/E Ratio
- ALNY N/A
- JD $9.63
- Revenue Growth
- ALNY 5.01
- JD 14.47
- 52 Week Low
- ALNY $205.87
- JD $29.90
- 52 Week High
- ALNY $495.55
- JD $46.45
- Technical
- Relative Strength Index (RSI)
- ALNY 49.33
- JD 48.27
- Support Level
- ALNY $456.90
- JD $33.82
- Resistance Level
- ALNY $485.36
- JD $35.06
- Average True Range (ATR)
- ALNY 16.80
- JD 0.74
- MACD
- ALNY -1.23
- JD 0.03
- Stochastic Oscillator
- ALNY 33.70
- JD 40.26
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
About JD JD.com Inc.
JD.com is the third-largest Chinese e-commerce platform by GMV in 2024. it offers a wide selection of authentic products with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.